Williams Mark E
Joslin Diabetes Center, Harvard Medical School, 1 Joslin Place, Boston, MA 02215, USA.
Curr Diab Rep. 2004 Dec;4(6):441-6. doi: 10.1007/s11892-004-0054-0.
Current treatment of the nephropathy complication of diabetes mellitus is suboptimal in halting the progression of the complex disease. Among the irreversible effects of sustained hyperglycemia is the heightened formation of advanced glycation end products (AGEs). The role of AGEs in diabetic nephropathy has been established by years of basic research. This article reports progression through human studies of the few AGE inhibitors that have reached clinical development, including pimagedine, pyridoxamine, and alagebrium.
目前糖尿病肾病并发症的治疗在阻止这种复杂疾病的进展方面并不理想。持续高血糖的不可逆影响之一是晚期糖基化终产物（AGEs）形成增加。多年的基础研究已证实了AGEs在糖尿病肾病中的作用。本文报告了包括氨基胍、吡哆胺和阿伐瑞林在内的少数已进入临床开发阶段的AGE抑制剂的人体研究进展。
